mPer2 antisense oligonucleotides inhibit mPER2 expression but not circadian rhythms of physiological activity in cultured suprachiasmatic nucleus neurons

Biochemical and Biophysical Research Communications
Takashi SugiyamaMasayuki Ikeda

Abstract

Various day-night rhythms, observed at molecular, cellular, and behavioral levels, are governed by an endogenous circadian clock, predominantly functioning in the hypothalamic suprachiasmatic nucleus (SCN). A class of clock genes, mammalian Period (mPer), is known to be rhythmically expressed in SCN neurons, but the correlation between mPER protein levels and autonomous rhythmic activity in SCN neurons is not well understood. Therefore, we blocked mPer translation using antisense phosphothioate oligonucleotides (ODNs) for mPer1 and mPer2 mRNAs and examined the effects on the circadian rhythm of cytosolic Ca2+ concentration and action potentials in SCN slice cultures. Treatment with mPer2 ODNs (20microM for 3 days) but not randomized control ODNs significantly reduced mPER2 immunoreactivity (-63%) in the SCN. Nevertheless, mPer1/2 ODNs treatment inhibited neither action potential firing rhythms nor cytosolic Ca2+ rhythms. These suggest that circadian rhythms in mPER protein levels are not necessarily coupled to autonomous rhythmic activity in SCN neurons.

References

Mar 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·W J SchwartzM T Morton
Jun 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·F K Stephan, I Zucker
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·A MiyawakiR Y Tsien
Aug 29, 2002·Nature·Steven M Reppert, David R Weaver
Oct 25, 2002·Nature·Sato HonmaKen-ichi Honma
Mar 8, 2003·Journal of Neuroendocrinology·D Holzberg, U Albrecht
Nov 25, 2003·Science·Shun YamaguchiHitoshi Okamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.